Vertex Pharmaceuticals (VRTX)
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
Something off on this page? Send us feedback.
Vertex is still overwhelmingly a cystic-fibrosis medicine company. One daily pill is replacing another inside that franchise, while pain, blood, hormone and kidney treatments are the attempt to build the next act. The old engine throws off the cash; most of the diversification story is still in launch mode or waiting for approval.
Item facts: FY2025 · year ended Dec 31, 2025, from filings, earnings calls and company pages.
Judgment weights, not filed revenue
The band summarizes business focus and direction. ~ marks estimates.
9 in detail · 10 more below
TRIKAFTA/KAFTRIO
Vertex's twice-daily cystic-fibrosis treatment brought in $10.313 billion in FY2025. It remains the cash engine; watch how quickly eligible patients move to the newer once-daily ALYFTREK.
Competes with SION-451 combinations (Sionna Therapeutics) · RCT2100 (ReCode Therapeutics)
In plain English
TRIKAFTA in the United States and KAFTRIO elsewhere are the same twice-daily treatment for cystic fibrosis, an inherited illness that makes sticky mucus clog the lungs and other organs. The pills help a faulty protein work better, easing the underlying problem rather than only treating symptoms.
Patients take it for years, so each prescription creates recurring sales through drug distributors and pharmacies that handle complex medicines. That dependable stream is Vertex's main cash engine, but it also makes the company unusually dependent on one medicine. A newer Vertex pill is now drawing many eligible patients away.
ALYFTREK
The once-daily successor to Vertex's older cystic-fibrosis pills reached $574 million in the second quarter of 2026. Much of that rise is patients switching within Vertex, so conversion speed matters more than apparent new demand.
Competes with SION-451 combinations (Sionna Therapeutics) · RCT2100 (ReCode Therapeutics)
In plain English
Think of ALYFTREK as Vertex remodeling its best-selling treatment into a once-a-day version. It treats the same inherited lung disease as TRIKAFTA/KAFTRIO and helps the same faulty protein work, but asks eligible patients to take medicine less often.
Doctors prescribe it and drug plans pay through the usual pharmacy channels. Most early users came from older Vertex regimens, so a sale gained here can mean a sale lost elsewhere in the franchise. The benefit for Vertex is keeping patients on its medicines while reaching more ages, gene changes and countries as approvals and insurance coverage widen.
CASGEVY
A one-time treatment that edits a patient's own blood-making cells brought in $116 million in FY2025. Growth depends on insurance approval, specialized treatment-center capacity and how quickly each personalized dose can be made.
Competes with LYFGENIA (Genetix Pharmaceuticals) · risto-cel/BEAM-101 (Beam Therapeutics)
In plain English
Unlike a pill refilled every month, CASGEVY is meant to be given once. Doctors collect a patient's blood-making stem cells, edit them to produce healthier blood, then return them after hospital preparation. It treats sickle-cell disease and an inherited anemia that otherwise requires regular transfusions.
The path from collection to treatment is long, so hospitals, manufacturers and insurers must line up before Vertex can complete a sale. More approved countries and treatment centers widen the doorway, but factory turnaround and center capacity set the pace. Vertex shares the treatment's costs and profits sixty-forty with CRISPR Therapeutics.
JOURNAVX
This short-course pill for serious sudden pain generated $60 million in its launch year. The opening is broad, but uptake rests on hospital prescribing, insurance coverage and winning use away from cheap established painkillers.
Competes with LTG-001 (Latigo Biotherapeutics) · STC-004 (Eli Lilly / SiteOne)
In plain English
A short spell of severe pain after an injury or procedure is the job for JOURNAVX. The pill blocks a signal switch on pain-sensing nerves without acting like an opioid, so doctors have another prescription choice for adults.
Hospitals often decide which medicines doctors can readily order, and pharmacies then fill a brief course rather than years of refills. Vertex earns from each prescription, making this a volume business: many doctors must try it, drug plans must cover it and patients must receive it quickly. By August 2026, coverage reached roughly 260 million people in the United States.
PALSONIFY
A once-daily pill for acromegaly joined Vertex with the September 2026 Crinetics purchase. Before the takeover, sales reached $24 million in 2026's second quarter; watch whether patients switch from injections and insurance approvals keep pace.
Competes with MYCAPSSA (Chiesi) · SOMATULINE DEPOT (Ipsen)
In plain English
Acromegaly happens when the body makes too much growth hormone, gradually enlarging bones and soft tissue. PALSONIFY turns down that hormone signal with a daily pill. Its practical appeal is simple: some people can swallow a tablet instead of returning for long-acting injections.
Specialist doctors start the prescription, while two pharmacies that handle complex medicines arrange delivery and insurance payment. Vertex gets recurring medicine sales as patients begin and stay on treatment. The market is small—about 20,000 diagnosed people in the United States—so the ramp depends on finding them, securing coverage and persuading suitable injection users to switch.
atumelnant
This daily pill is still in trials for two rare hormone disorders. Vertex says atumelnant and PALSONIFY together could top $5 billion in yearly sales, but that is a company goal and trial results come first.
Competes with CRENESSITY/crinecerfont (Neurocrine) · relacorilant (Corcept)
In plain English
Two rare hormone problems give atumelnant two possible routes. In one, an inherited disorder pushes the body to overproduce certain hormones; in the other, the body makes too much cortisol. The experimental pill blocks the signal that drives both.
There are no sales yet. If studies succeed and regulators approve it, hormone specialists could prescribe a daily treatment for years, creating repeat pharmacy revenue. Vertex estimates about 17,000 addressable patients in the United States for the inherited disorder, but the market remains small and competitors already attack the same illnesses in different ways.
povetacicept
A monthly shot designed to stop the immune system from damaging the kidneys has no sales yet. Its first approval decision is due by November 30, 2026; rival VOYXACT is already approved.
Competes with VOYXACT/sibeprenlimab (Otsuka) · telitacicept (Vor Bio / RemeGen)
In plain English
Some kidney diseases begin when the body's defenses mistakenly create harmful proteins that lodge in the kidneys. Povetacicept is a monthly injection designed to reduce those proteins, with a self-injecting pen planned so patients can treat themselves at home.
Kidney specialists would prescribe it to slow damage, and long-term monthly use could produce recurring sales. First, Vertex needs approval and evidence that the benefit holds up. Otsuka's VOYXACT reached the market in 2025, so povetacicept must earn a place rather than enter an empty field. Other studies are testing it in additional immune-driven illnesses.
inaxaplin
This experimental daily pill targets kidney damage tied to inherited changes in a gene called APOL1. Vertex sees roughly a quarter-million U.S. patients across two groups; the next test is whether ongoing studies show lasting kidney protection.
Competes with MZE829 (Maze Therapeutics) · FARXIGA/dapagliflozin (AstraZeneca)
In plain English
A faulty version of the APOL1 gene can make kidneys scar and lose function. Inaxaplin is a daily pill designed to block the harmful protein made by that gene, attacking a cause of disease rather than treating kidney decline broadly.
The commercial path begins with a genetic test: doctors must identify who carries the risky variants before prescribing. If the trials succeed and the pill is approved, kidney specialists could create years of repeat prescriptions. Maze Therapeutics is already testing another pill aimed at the same protein, while AstraZeneca's FARXIGA treats chronic kidney disease more broadly.
zimislecel
Lab-made insulin-producing cells could help roughly 60,000 people with severe type 1 diabetes avoid dangerous blood-sugar crashes. There is no revenue yet, and manufacturing consistency remains the immediate test after dosing resumed.
Competes with LANTIDRA/donislecel (CellTrans) · SC451/UP421 (Sana Biotechnology)
In plain English
For a small group with type 1 diabetes, insulin treatment still cannot prevent repeated, dangerous drops in blood sugar. Zimislecel replaces the lost insulin-making cells with cells grown in a factory, then placed into the body at a specialist center. Patients must also take medicines that quiet the immune system.
If approved, Vertex would sell each cell dose while treatment centers handle the procedure. That makes reliable manufacturing and center capacity as important as medical benefit. A production investigation paused dosing before it resumed, and alternatives include scarce donor cells and experimental cells designed to hide from immune attack.
TRIKAFTA/KAFTRIOVertex's twice-daily cystic-fibrosis treatment brought in $10.313 billion in FY2025. It remains the cash engine; watch how quickly eligible patients move to the newer once-daily ALYFTREK.Vertex's twice-daily cystic-fibrosis treatment brought in $10.313 billion in FY2025. It remains the cash engine; watch how quickly eligible patients move to the newer once-daily ALYFTREK.
In plain English
TRIKAFTA in the United States and KAFTRIO elsewhere are the same twice-daily treatment for cystic fibrosis, an inherited illness that makes sticky mucus clog the lungs and other organs. The pills help a faulty protein work better, easing the underlying problem rather than only treating symptoms.
Patients take it for years, so each prescription creates recurring sales through drug distributors and pharmacies that handle complex medicines. That dependable stream is Vertex's main cash engine, but it also makes the company unusually dependent on one medicine. A newer Vertex pill is now drawing many eligible patients away.
Competes with SION-451 combinations (Sionna Therapeutics) · RCT2100 (ReCode Therapeutics)
ALYFTREKThe once-daily successor to Vertex's older cystic-fibrosis pills reached $574 million in the second quarter of 2026. Much of that rise is patients switching within Vertex, so conversion speed matters more than apparent new demand.The once-daily successor to Vertex's older cystic-fibrosis pills reached $574 million in the second quarter of 2026. Much of that rise is patients switching within Vertex, so conversion speed matters more than apparent new demand.
In plain English
Think of ALYFTREK as Vertex remodeling its best-selling treatment into a once-a-day version. It treats the same inherited lung disease as TRIKAFTA/KAFTRIO and helps the same faulty protein work, but asks eligible patients to take medicine less often.
Doctors prescribe it and drug plans pay through the usual pharmacy channels. Most early users came from older Vertex regimens, so a sale gained here can mean a sale lost elsewhere in the franchise. The benefit for Vertex is keeping patients on its medicines while reaching more ages, gene changes and countries as approvals and insurance coverage widen.
Competes with SION-451 combinations (Sionna Therapeutics) · RCT2100 (ReCode Therapeutics)
CASGEVYA one-time treatment that edits a patient's own blood-making cells brought in $116 million in FY2025. Growth depends on insurance approval, specialized treatment-center capacity and how quickly each personalized dose can be made.A one-time treatment that edits a patient's own blood-making cells brought in $116 million in FY2025. Growth depends on insurance approval, specialized treatment-center capacity and how quickly each personalized dose can be made.
In plain English
Unlike a pill refilled every month, CASGEVY is meant to be given once. Doctors collect a patient's blood-making stem cells, edit them to produce healthier blood, then return them after hospital preparation. It treats sickle-cell disease and an inherited anemia that otherwise requires regular transfusions.
The path from collection to treatment is long, so hospitals, manufacturers and insurers must line up before Vertex can complete a sale. More approved countries and treatment centers widen the doorway, but factory turnaround and center capacity set the pace. Vertex shares the treatment's costs and profits sixty-forty with CRISPR Therapeutics.
Competes with LYFGENIA (Genetix Pharmaceuticals) · risto-cel/BEAM-101 (Beam Therapeutics)
JOURNAVXThis short-course pill for serious sudden pain generated $60 million in its launch year. The opening is broad, but uptake rests on hospital prescribing, insurance coverage and winning use away from cheap established painkillers.This short-course pill for serious sudden pain generated $60 million in its launch year. The opening is broad, but uptake rests on hospital prescribing, insurance coverage and winning use away from cheap established painkillers.
In plain English
A short spell of severe pain after an injury or procedure is the job for JOURNAVX. The pill blocks a signal switch on pain-sensing nerves without acting like an opioid, so doctors have another prescription choice for adults.
Hospitals often decide which medicines doctors can readily order, and pharmacies then fill a brief course rather than years of refills. Vertex earns from each prescription, making this a volume business: many doctors must try it, drug plans must cover it and patients must receive it quickly. By August 2026, coverage reached roughly 260 million people in the United States.
Competes with LTG-001 (Latigo Biotherapeutics) · STC-004 (Eli Lilly / SiteOne)
PALSONIFYA once-daily pill for acromegaly joined Vertex with the September 2026 Crinetics purchase. Before the takeover, sales reached $24 million in 2026's second quarter; watch whether patients switch from injections and insurance approvals keep pace.A once-daily pill for acromegaly joined Vertex with the September 2026 Crinetics purchase. Before the takeover, sales reached $24 million in 2026's second quarter; watch whether patients switch from injections and insurance approvals keep pace.
In plain English
Acromegaly happens when the body makes too much growth hormone, gradually enlarging bones and soft tissue. PALSONIFY turns down that hormone signal with a daily pill. Its practical appeal is simple: some people can swallow a tablet instead of returning for long-acting injections.
Specialist doctors start the prescription, while two pharmacies that handle complex medicines arrange delivery and insurance payment. Vertex gets recurring medicine sales as patients begin and stay on treatment. The market is small—about 20,000 diagnosed people in the United States—so the ramp depends on finding them, securing coverage and persuading suitable injection users to switch.
Competes with MYCAPSSA (Chiesi) · SOMATULINE DEPOT (Ipsen)
atumelnantThis daily pill is still in trials for two rare hormone disorders. Vertex says atumelnant and PALSONIFY together could top $5 billion in yearly sales, but that is a company goal and trial results come first.This daily pill is still in trials for two rare hormone disorders. Vertex says atumelnant and PALSONIFY together could top $5 billion in yearly sales, but that is a company goal and trial results come first.
In plain English
Two rare hormone problems give atumelnant two possible routes. In one, an inherited disorder pushes the body to overproduce certain hormones; in the other, the body makes too much cortisol. The experimental pill blocks the signal that drives both.
There are no sales yet. If studies succeed and regulators approve it, hormone specialists could prescribe a daily treatment for years, creating repeat pharmacy revenue. Vertex estimates about 17,000 addressable patients in the United States for the inherited disorder, but the market remains small and competitors already attack the same illnesses in different ways.
Competes with CRENESSITY/crinecerfont (Neurocrine) · relacorilant (Corcept)
povetaciceptA monthly shot designed to stop the immune system from damaging the kidneys has no sales yet. Its first approval decision is due by November 30, 2026; rival VOYXACT is already approved.A monthly shot designed to stop the immune system from damaging the kidneys has no sales yet. Its first approval decision is due by November 30, 2026; rival VOYXACT is already approved.
In plain English
Some kidney diseases begin when the body's defenses mistakenly create harmful proteins that lodge in the kidneys. Povetacicept is a monthly injection designed to reduce those proteins, with a self-injecting pen planned so patients can treat themselves at home.
Kidney specialists would prescribe it to slow damage, and long-term monthly use could produce recurring sales. First, Vertex needs approval and evidence that the benefit holds up. Otsuka's VOYXACT reached the market in 2025, so povetacicept must earn a place rather than enter an empty field. Other studies are testing it in additional immune-driven illnesses.
Competes with VOYXACT/sibeprenlimab (Otsuka) · telitacicept (Vor Bio / RemeGen)
inaxaplinThis experimental daily pill targets kidney damage tied to inherited changes in a gene called APOL1. Vertex sees roughly a quarter-million U.S. patients across two groups; the next test is whether ongoing studies show lasting kidney protection.This experimental daily pill targets kidney damage tied to inherited changes in a gene called APOL1. Vertex sees roughly a quarter-million U.S. patients across two groups; the next test is whether ongoing studies show lasting kidney protection.
In plain English
A faulty version of the APOL1 gene can make kidneys scar and lose function. Inaxaplin is a daily pill designed to block the harmful protein made by that gene, attacking a cause of disease rather than treating kidney decline broadly.
The commercial path begins with a genetic test: doctors must identify who carries the risky variants before prescribing. If the trials succeed and the pill is approved, kidney specialists could create years of repeat prescriptions. Maze Therapeutics is already testing another pill aimed at the same protein, while AstraZeneca's FARXIGA treats chronic kidney disease more broadly.
Competes with MZE829 (Maze Therapeutics) · FARXIGA/dapagliflozin (AstraZeneca)
zimislecelLab-made insulin-producing cells could help roughly 60,000 people with severe type 1 diabetes avoid dangerous blood-sugar crashes. There is no revenue yet, and manufacturing consistency remains the immediate test after dosing resumed.Lab-made insulin-producing cells could help roughly 60,000 people with severe type 1 diabetes avoid dangerous blood-sugar crashes. There is no revenue yet, and manufacturing consistency remains the immediate test after dosing resumed.
In plain English
For a small group with type 1 diabetes, insulin treatment still cannot prevent repeated, dangerous drops in blood sugar. Zimislecel replaces the lost insulin-making cells with cells grown in a factory, then placed into the body at a specialist center. Patients must also take medicines that quiet the immune system.
If approved, Vertex would sell each cell dose while treatment centers handle the procedure. That makes reliable manufacturing and center capacity as important as medical benefit. A production investigation paused dosing before it resumed, and alternatives include scarce donor cells and experimental cells designed to hide from immune attack.
Competes with LANTIDRA/donislecel (CellTrans) · SC451/UP421 (Sana Biotechnology)
Named in filings, launches and programs
- KALYDECOProductOlder cystic-fibrosis pill; with ORKAMBI and SYMDEKO/SYMKEVI, the three brought in $645 million in FY2025.
- ORKAMBIProductOlder two-drug cystic-fibrosis treatment that still serves people with eligible gene changes inside the mature franchise.
- SYMDEKO/SYMKEVIProductUnited States and international names for another older two-drug cystic-fibrosis treatment that remains on sale.
- VX-828Product · Pre-revenueNext-generation cystic-fibrosis candidate in an early human test, with results expected in the second half of 2026.
- VX-581Product · Pre-revenueEarly cystic-fibrosis candidate intended to become part of a future combination treatment.
- VX-272Product · Pre-revenueAnother early cystic-fibrosis candidate in the program meant to renew Vertex's core franchise.
- VX-993Product · Pre-revenuePain-pill candidate dropped as a stand-alone short-course treatment after a failed study; a diabetic nerve-pain study remained underway at the last update.
- VX-017Product · Pre-revenueLab-grown insulin-cell program designed to work across blood types and widen access beyond zimislecel.
- VX-407Product · Pre-revenueDaily pill being tested for a genetically defined form of inherited kidney cyst disease.
- VX-670Product · Pre-revenueEarly genetic medicine for myotonic dystrophy, an inherited muscle disorder, with initial study results expected in the second half of 2026.
KALYDECOProduct
Older cystic-fibrosis pill; with ORKAMBI and SYMDEKO/SYMKEVI, the three brought in $645 million in FY2025.
ORKAMBIProduct
Older two-drug cystic-fibrosis treatment that still serves people with eligible gene changes inside the mature franchise.
SYMDEKO/SYMKEVIProduct
United States and international names for another older two-drug cystic-fibrosis treatment that remains on sale.
VX-828Product · Pre-revenue
Next-generation cystic-fibrosis candidate in an early human test, with results expected in the second half of 2026.
VX-581Product · Pre-revenue
Early cystic-fibrosis candidate intended to become part of a future combination treatment.
VX-272Product · Pre-revenue
Another early cystic-fibrosis candidate in the program meant to renew Vertex's core franchise.
VX-993Product · Pre-revenue
Pain-pill candidate dropped as a stand-alone short-course treatment after a failed study; a diabetic nerve-pain study remained underway at the last update.
VX-017Product · Pre-revenue
Lab-grown insulin-cell program designed to work across blood types and widen access beyond zimislecel.
VX-407Product · Pre-revenue
Daily pill being tested for a genetically defined form of inherited kidney cyst disease.
VX-670Product · Pre-revenue
Early genetic medicine for myotonic dystrophy, an inherited muscle disorder, with initial study results expected in the second half of 2026.